Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced the presentation of …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing novel investigational products that help harness the body’s own immune system to fight cancer, announced …
Peregrine Pharmaceuticals (NASDAQ:PPHM) (NASDAQ:PPHMP) announced that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of data from clinical translational studies of the company’s phosphatidylserine (PS)-targeting immunotherapy bavituximab. Initial data from a …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting …
Peregrine Pharmaceuticals (NASDAQ:PPHM), announced the peer-reviewed publication of clinical data from a Phase I investigator-sponsored trial evaluating the company's lead investigational immunotherapy bavituximab plus …
(Marketwired) — 01/16/15 — Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), today announced the presentation of clinical data related to the company’s immuno-oncology development program and …
In a research report released Thursday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $5 price …
In a research report released Wednesday, MLV analyst George Zavoico reiterated a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $3.50 price target, following presentation …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $5 price target, as the company presented new data from …
